Latest1 information on COVID-19
©2022 Stanford Medicine
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Not Recruiting
Trial ID: NCT00959647
Purpose
This was a multicenter, open-label extension study. Patients who received vismodegib
(GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who
continued to receive vismodegib at the time the parent study closed were eligible for
continued treatment in this protocol.
Official Title
An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study
Stanford Investigator(s)
Anthony Oro, MD, PhD
Eugene and Gloria Bauer Professor
Bernice Kwong, MD
Clinical Professor, Dermatology
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Anne Lynn S. Chang, MD
Professor of Dermatology
Eligibility
This study only enrolled participants who took part in previous studies of vismodegib
conducted by Genentech.
Inclusion Criteria:
- Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study
or continued to receive vismodegib at the time the Genentech-sponsored parent study
closed.
- Expectation by the investigator that the participant may continue to benefit from
additional vismodegib treatment.
Exclusion Criteria:
- Intervening anti-tumor therapy not specified in the parent study (ie,
non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or
photodynamic therapy).
Intervention(s):
drug: bevacizumab
drug: FOLFIRI
drug: FOLFOX
drug: Vismodegib
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061